18Jul/13

Lupin to market MSD's pneumococcal vaccine in India – Business Standard


Business Standard

Lupin to market MSD’s pneumococcal vaccine in India
Business Standard
“Adults with comorbid conditions such as chronic lung disease, diabetes, chronic heart diseases, chronic liver diseases and immune compromised diseases, as well as adults aged more than 65, are at increased risk of pneumococcal disease, compared to 
Lupin to market MSD’s 23-valent Pneumococcal Polysaccharide Vaccine for IndiaHindu Business Line
MSD, Lupin enter strategic alliance to co-market MSD’s 23-valent PPV for pharmabiz.com

all 13 news articles »

18Jul/13

Lupin to market MSD's 23-valent Pneumococcal Polysaccharide Vaccine for India – Hindu Business Line

Lupin to market MSD’s 23-valent Pneumococcal Polysaccharide Vaccine for India
Hindu Business Line
Adults with co morbid conditions like chronic lung disease, diabetes, chronic heart diseases, chronic liver diseases, immune compromised diseases as well as adults more than 65 years of age are at increased risk for pneumococcal diseases than healthy 

and more »